Peter R van Dijk
University Medical Center Groningen
77 Papers
110 Citations
Peter R van Dijk is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Medicine & Diabetes mellitus. The author has an hindex of 13, co-authored 50 publications. Previous affiliations of Peter R van Dijk include University of Groningen.
Chat about Author
Papers
Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)
Marion J Fokkert,Peter R van Dijk,Mireille A Edens,Eglantine Barents,Jeanine Mollema,Robbert J. Slingerland,Reinold O. B. Gans,Henk J. G. Bilo +7 more
TL;DR: The FreeStyle Libre is a flash glucose monitoring (FSL-FGM) system as mentioned in this paper, which may provide benefits in terms of improved glycemic control and decreased disease burden, compared with finger-prick based self-monitoring of blood glucose.
137
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
Gijs W. D. Landman,Geertruide H. de Bock,Kornelis J. J. van Hateren,Peter R van Dijk,Klaas H. Groenier,Rijk O. B. Gans,Sebastiaan T. Houweling,Henk J. G. Bilo,Nanne Kleefstra +8 more
TL;DR: The number of severe hypoglycemic episodes was extremely low, and gliclazide appears at least equally effective compared to other glucose lowering agents, and effect estimates on weight were limited by publication bias.
The Effects of a Mobile Phone Application on Quality of Life in Patients With Type 1 Diabetes Mellitus: A Randomized Controlled Trial.
I. Drion,Loes R. Pameijer,Peter R van Dijk,Klaas H. Groenier,Nanne Kleefstra,Henk J. G. Bilo +5 more
TL;DR: The use of the DBEES application in the management of patients with T1DM for 3 months yields no alterations in quality of life compared to the standard paper diary, as measured by the RAND-36 questionnaire.
64
Serum Calcification Propensity and the Risk of Cardiovascular and All-Cause Mortality in the General Population: The PREVEND Study.
Coby Eelderink,Charlotte A Te Velde-Keyzer,Anne-Roos S. Frenay,Emma A. Vermeulen,Matthias Bachtler,Parisa Aghagolzadeh,Parisa Aghagolzadeh,Peter R van Dijk,Ron T. Gansevoort,Marc G. Vervloet,Jan-Luuk Hillebrands,Stephan J. L. Bakker,Harry van Goor,Andreas Pasch,Martin H. de Borst +14 more
TL;DR: Serum T50 is independently associated with an increased risk of cardiovascular mortality in the general population and thus may be an early and potentially modifiable risk marker for cardiovascular mortality.
Device-guided breathing as treatment for hypertension in type 2 diabetes mellitus: a randomized, double-blind, sham-controlled trial.
Gijs W. D. Landman,I. Drion,Kornelis J. J. van Hateren,Peter R van Dijk,Susan J. J. Logtenberg,Jan Lambert,Klaas H. Groenier,Henk J. G. Bilo,Nanne Kleefstra +8 more
TL;DR: On the basis of this study, together with results from all but one previous trial, device-guided lowering of breathing frequency does not appear to be a viable nonpharmacologic option for hypertension treatment.
43